kadmon.comDeveloping transformative therapies for immune disorders, fibrotic diseases and cancer - Kadmon Hold
kadmon.com Profile
kadmon.com
Sub Domains:investors.kadmon.com
Title:Developing transformative therapies for immune disorders, fibrotic diseases and cancer - Kadmon Hold
Description:-- -- -- Toggle Navigation Search: About Us Our Company Leadership Board of Directors Kadmon Commitment Contact Clinical Pipeline About Belumosudil Belumosudil in cGVHD Belumosudil in Systemic Scleros
Discover kadmon.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
kadmon.com Information
Website / Domain: |
kadmon.com |
HomePage size: | 43.603 KB |
Page Load Time: | 0.129633 Seconds |
Website IP Address: |
64.207.154.158 |
Isp Server: |
Media Temple Inc. |
kadmon.com Ip Information
Ip Country: |
United States |
City Name: |
Culver City |
Latitude: |
34.017185211182 |
Longitude: |
-118.39282989502 |
kadmon.com Keywords accounting
kadmon.com Httpheader
Server: nginx |
Date: Sun, 20 Dec 2020 15:30:18 GMT |
Content-Type: text/html; charset=UTF-8 |
Content-Length: 6902 |
Connection: keep-alive |
Last-Modified: Wed, 16 Dec 2020 19:54:27 GMT |
Accept-Ranges: bytes |
Vary: Accept-Encoding |
Content-Encoding: gzip |
Cache-Control: max-age=0, no-cache, no-store, must-revalidate |
Pragma: no-cache |
Expires: Mon, 29 Oct 1923 20:30:00 GMT |
X-Powered-By: PleskLin |
kadmon.com Meta Info
charset="utf-8"/ |
content="IE=edge" http-equiv="X-UA-Compatible"/ |
content="width=device-width, initial-scale=1" name="viewport"/ |
content="josh@comocreative.com" name="author"/ |
content="7 days" name="revisit-after"/ |
content="noindex,follow" name="robots" |
content="en_US" property="og:locale" |
content="website" property="og:type" |
content="Developing transformative therapies for immune disorders, fibrotic diseases and cancer - Kadmon Holdings, Inc." property="og:title" |
content="https://kadmon.com/" property="og:url"/ |
content="Kadmon Holdings, Inc." property="og:site_name"/ |
content="https://kadmon.com/wp-content/uploads/bg-home-top-min.jpg" property="og:image"/ |
content="https://kadmon.com/wp-content/uploads/bg-home-top-min.jpg" property="og:image:secure_url"/ |
content="1920" property="og:image:width"/ |
content="1080" property="og:image:height"/ |
content="summary_large_image" name="twitter:card"/ |
content="Developing transformative therapies for immune disorders, fibrotic diseases and cancer - Kadmon Holdings, Inc." name="twitter:title"/ |
content="https://kadmon.com/wp-content/uploads/bg-home-top-min.jpg" name="twitter:image"/ |
content="https://kadmon.com/wp-content/uploads/favicon-min.png" name="msapplication-TileImage"/ |
64.207.154.158 Domains
kadmon.com Similar Website
Domain |
WebSite Title |
kadmon.com | Developing transformative therapies for immune disorders, fibrotic diseases and cancer - Kadmon Hold |
progenics.com | Progenics Pharmaceuticals | Developing Innovative Cancer Therapies |
healthcoalition.com | Home Page HCI - Oncolytics | immune globulins | coagulation products | hyper-immune pharmaceuticals |
boulderkidspot.com | KidSPOT Pediatric Therapies - KidSPOT Pediatric Therapies - discovering potential. inspiring growth. |
venturebeat.com | VentureBeat | Transformative tech coverage that matters |
firmstep.com | Deliver Transformative Technology for Citizens and Staff |
rpharm-us.com | R-PHARM US | Delivering specialty medicines for cancer and chronic immune diseases |
akamai.covidien.com | Medtronic Minimally Invasive Therapies |
mycivt.civtedu.org | College of Integrative Veterinary Therapies |
professional.medtronic.com | Restorative Therapies Group | Medtronic |
civtedu.org | College of Integrative Veterinary Therapies |
covidien.com | Medtronic Minimally Invasive Therapies |
immunology.conferenceseries.com | immunology Conferences 2020 | Immune System Conferences virology confrerence2020| carona virus conf |
pcacorp.com | Patient Care America – Nutritional Therapies |
login.pcacorp.com | Dietitian Login PCA – Nutritional Therapies |
kadmon.com Traffic Sources Chart
kadmon.com Alexa Rank History Chart
kadmon.com Html To Plain Text
-- -- -- Toggle Navigation Search: About Us Our Company Leadership Board of Directors Kadmon Commitment Contact Clinical Pipeline About Belumosudil Belumosudil in cGVHD Belumosudil in Systemic Sclerosis About KD033 Clinical Trials Science Preclinical Pipeline Biologics Monoclonal Antibody Discovery Platform IL-15 Platform Small Molecules Structure-Based Drug Design Publications and Posters Products Investors Investors Home News & Events Press Releases Presentations & Events Stock Information Stock Quote & Chart Analyst Coverage Historic Price Lookup Financials & Filings Corporate Governance Documents & Charters Leadership Board of Directors Investor Resources Investor/Media FAQs Contact Us Email Alerts Careers Search: Contact Developing transformative therapies for immune disorders, fibrotic diseases and cancer About Us Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. We are developing treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Learn More News December 6, 2020 Kadmon Announces 12 Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting November 30, 2020 Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease November 24, 2020 Kadmon to Host Virtual Key Opinion Leader Event at the 62nd ASH Annual Meeting Belumosudil We have a deep understanding of the pathways involved in inflammation and fibrosis. Our late-stage product candidate, Belumosudil, is an inhibitor of ROCK2, a signaling pathway that modulates key inflammatory and fibrotic processes. A pivotal study of belumosudil is underway in patients with chronic graft-versus-host disease (cGVHD). A Phase 2 clinical trial of belumosudil is also underway in patients with systemic sclerosis (SSc). Read More Our Science Biologics IL-15 Platform Learn More Biologics Monoclonal Antibody Discovery Platform Learn More Small Molecule Structure-Based Drug Design Learn More 450 East 29th Street New York, New York 10016 55 Cambridge Parkway, Suite 300E Cambridge, Massachusetts 02142 119 Commonwealth Drive Warrendale, Pennsylvania 15086 Site Map Privacy Policy Terms of Use California Compliance © 2020 Kadmon Holdings, Inc.. All Rights Reserved....
kadmon.com Whois
"domain_name": [
"KADMON.COM",
"kadmon.com"
],
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2020-04-11 15:23:05",
"2020-04-11 15:23:03"
],
"creation_date": "2002-04-10 20:52:17",
"expiration_date": "2021-04-10 20:52:17",
"name_servers": [
"EDNS4.ULTRADNS.BIZ",
"EDNS4.ULTRADNS.COM",
"EDNS4.ULTRADNS.NET",
"EDNS4.ULTRADNS.ORG"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": [
"abuse@godaddy.com",
"kadmon.com@domainsbyproxy.com"
],
"dnssec": "unsigned",
"name": "Registration Private",
"org": "Domains By Proxy, LLC",
"address": [
"DomainsByProxy.com",
"14455 N. Hayden Road"
],
"city": "Scottsdale",
"state": "Arizona",
"zipcode": "85260",
"country": "US"